Annotation
Rotavirus: a new vaccine for the UK?
| The first 150 words of the full text of this article appear below. |
| |
Article |
|---|
Each year it is estimated that group A rotavirus infection causes around 800 000 deaths worldwide from gastroenteritis in children under 5 years of age.1 Symptoms usually accompany primary infection, which is followed by protection against subsequent symptomatic infection.2 For this reason, the peak attack rates for symptomatic rotavirus disease occur in children between 6 and 12 months of age.3
The development of rotavirus vaccines has focused mainly on the
use of orally administered live attenuated rotaviruses from non-human
hosts. A recent modification was the production of tetravalent vaccines
containing "reassortant" strains of rotavirus
(TV-RRV).4 These reassortants contain 10 genes from rhesus
monkey strains and one gene that codes for human serotypes G1, G2, and
G4; the rhesus rotavirus itself provides coverage for serotype
G3.4 Efficacy studies in the USA, Finland, and Venezuela
have demonstrated that TV-RRV provides good protection against severe
rotavirus diarrhoea.5-7 In the USA, TV-RRV is now
recommended for routine use
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.



